-

PeterMD and Lorient Partner to Accelerate Growth of the Nation’s First Fully Integrated Medicine 3.0 Platform

Investment will scale PeterMD’s Medicine 3.0 platform in a fast-growing $200 billion market as consumers prioritize affordable, personalized and preventative healthcare

VERO BEACH, Fla.--(BUSINESS WIRE)--PeterMD, a direct-to-consumer health optimization platform trusted by more than 400,000 patients, today announced a majority equity investment from Lorient, a private investment firm focused exclusively on healthcare service and technology companies, in conjunction with Emanate. As part of the partnership, PeterMD welcomes David Prokupek, Executive Chair of American Family Care and Reveal Dental Partners and former CEO of Ideal Image, to its Board of Directors as Executive Chair.

Lorient’s investment will help accelerate PeterMD’s national expansion in the rapidly growing $200 billion Medicine 3.0 marketplace. Medicine 3.0 describes the broader evolution in healthcare, emphasizing prevention, personalization and earlier intervention to proactively improve long-term patient outcomes rather than waiting to treat symptoms until after they appear.

“Since founding PeterMD in 2014, we have evolved the platform from a narrow focus on hormone imbalances to offer patients a team of experts, complete control and visibility into their health and continuous medical guidance in one place,” said Bryan and Sarah Henry, Co-Founders of PeterMD. “That’s what people want, and that’s exactly what we’ve built. With increased consumer focus on and demand for hormone therapies, GLP-1s, peptides and other drugs designed to boost longevity, repair cellular damage and treat metabolic conditions, we are excited to work with Lorient and Emanate to continue scaling our platform and further solidify our position as the one-stop-shop for people to optimize their health.”

PeterMD has built a fully integrated national telehealth platform, bringing together advanced diagnostics and more than 60 biomarker lab panels, personalized treatments spanning hormone therapy, weight loss and peptide protocols, and continuous primary care – all through an easy-to-use, digital experience.

“As part of our thematic-first approach, Lorient spent over a year researching and meeting with companies in the Med 3.0 industry. We believe PeterMD represents the future of healthcare – a highly scalable platform with a patient-centric approach, adhering to the highest clinical standards,” said Eric Gonzalez, Principal at Lorient. “Bryan and Sarah share a relentless focus on bridging the gap between cutting-edge longevity science and patient accessibility. Together, with David’s experience scaling leading consumer-wellness platforms, we’re excited to take part in PeterMD’s next chapter of growth.”

About PeterMD

PeterMD is a leading direct-to-consumer health optimization and precision medicine platform trusted by more than 400,000 patients to help them feel better, catch disease early, and live longer, healthier lives with personalized plans tied to their own biology. PeterMD empowers patients with diagnostic-driven insights and customized solutions spanning advanced blood and DNA diagnostics, hormone health, weight loss, sexual wellness, and longevity.

About Lorient

Lorient is a private investment firm specializing in operationally intensive healthcare businesses. The firm invests in majority and control positions, partnering with founders and aligned operating leadership to deploy the L1OS — the Lorient Operating System — a structured, repeatable operational framework built from direct operating experience in healthcare services. Powered by Morpheus, the firm's proprietary data platform, the L1OS translates operational discipline into measurable outcomes from day one, enabling consistent performance across distributed teams and multi-site environments. Visit us at: https://lorientcap.com/.

About Emanate

Emanate is a lower middle-market investment firm focused on partnering with founder, owner, and operator-led businesses that are at an inflection point in their growth journey. Emanate’s approach centers on building strong, long-term partnerships with exceptional management teams to unlock value, drive sustainable performance, and position companies for lasting success. Visit us at: https://www.emanateinc.co/

Contacts

Media Contact:
ICR for Lorient
LorientPR@icrinc.com

Lorient and PeterMD LogoLorient and PeterMD Logo

Lorient and PeterMD


Release Summary
PeterMD and Lorient Partner to Accelerate Growth of the Nation’s First Fully Integrated Medicine 3.0 Platform
Release Versions

Contacts

Media Contact:
ICR for Lorient
LorientPR@icrinc.com

Back to Newsroom